AI Article Synopsis
- The study examined 77 patients with primary amyloid renal disease to assess the progression to end-stage renal disease (ESRD), renal response (RR), and overall survival (OS) in the context of emerging monoclonal antibody therapies.
- Key findings showed that a significant portion of patients showed improvements with treatments like bortezomib and stem cell transplants, with a 34% rate of progression to ESRD and a majority achieving satisfactory hematologic response.
- The research highlighted the need for innovative strategies to address amyloid-related organ dysfunction, as traditional anti-plasma cell therapies offered only limited benefits despite some positive outcomes.
Article Abstract
Background: Outcomes in primary amyloid renal patients are of interest as the era of monoclonal antibody therapies begins.
Patients And Methods: We studied 77 consecutive primary amyloid renal patients (58% men) for renal progression (end stage renal disease [ESRD]), renal response (RR), and overall survival (OS).
Results: At diagnosis median age was 63 (range, 35-81) years, estimated glomerular filtration rate 70 mL/min (range, 5-114), difference between involved and uninvolved free light chains 127 mg/L (range, 1-9957), ESRD 4%, renal stage 2 and 3 78%, and cardiac stage 2 and 3 56%. Ninety-six percent received bortezomib and 44% stem cell transplantation as well as bortezomib, 68% achieved complete or very good partial hematologic response (CR/VGPR), 34% had ESRD, and 39% RR. Median times to ESRD and RR were 18 (range, 3-81) and 12 (range, 2-30) months, respectively. Median OS was not reached in this cohort and was not reached from onset of ESRD. More than two-thirds of patients with ESRD also achieved CR/VGPR. In those without ESRD at diagnosis, baseline creatinine and absent RR predicted progression to ESRD in multivariate Cox regression analysis, whereas CR/VGPR predicted RR. In multivariate Cox regression analysis, cardiac stage and achievement of CR/VGPR predicted OS, enabling construction of a prognostic model.
Conclusion: Anti-plasma cell therapies provide a definite albeit limited benefit and new approaches to amyloid-related organ dysfunction are needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.clml.2017.06.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!